Evaluating Technologies Found Cost Effective at Zero Price

This article explains why some technologies may fail to demonstrate cost effectiveness even when the acquisition price is set to zero, raising both methodological and ethical questions for health technology assessment (HTA) agencies. Learn more here. (Source: Sarah Davis, Dr. Ron Akehurst, Health Policy)

You might also be interested in:

Stanford Center for Health Education Launches Online Program… 08/11/2020
What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
Toward A More Precise Public Health Strategy in the Battle… 08/13/2020
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020
Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020